• Exceeded recruitment target for Phase III insomnia trial interim analysis
• Independent Data Monitoring Board appointed, interim analysis on track for June 2026
• Commercial partner Sandoz AG in place for Australian market

Avecho Biotechnology Limited (ASX: AVE) has presented its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2026. The company exceeded the recruitment target for the interim analysis cohort of its pivotal Phase III clinical trial testing its TPM-enhanced cannabidiol (CBD) soft-gel capsule for the treatment of insomnia, with 244 patients randomised - 16% above the interim analysis target. This larger cohort will increase the statistical power of the interim analysis. The interim analysis results remain on track for June 2026. Avecho has appointed an independent Data Monitoring Board (DMB) comprised of external clinical and biostatistical experts to review the unblinded interim trial data and report its findings and recommendations to the company. The DMB met for the first time in February 2026 to complete its governance and charter arrangements. Commercial rights to the Australian market are already committed to Sandoz AG under a 10-year development and licensing agreement executed in March 2025. The company's CBD soft-gel patent applications have also been allowed by the United States Patent and Trademark Office and European Patent Office, providing additional intellectual property protection. At 31 March 2026, Avecho held a cash balance of $4.3 million, with an expected cash runway of 4.89 quarters.